Join our daily newsletter At The Bell to receive exclusive market insights
- Imugene (IMU) has begun dosing the second cohort of patients in the phase one clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx
- The study in patients with non-small cell lung cancer is assessing three different doses of the possible treatment
- The primary objective is to determine the optimal dosing of PD1-Vaxx as a monotherapy but will also measure efficacy, tolerability and immune response
- The study was able to progress to the mid-dose cohort after the review committee found the immunotherapy candidate was safe with no dose-limiting adverse reactions in the first cohort
- Shares have been trading 5 per cent higher at 10.5 cents
Imugene (IMU) has begun dosing the second cohort of patients in the phase one clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx.
The first-in-human, multi-centre trial in patients with non-small cell lung cancer is assessing three different doses of the possible treatment.
The primary objective is to determine the optimal dosing of PD1-Vaxx as a monotherapy but will also measure efficacy, tolerability and immune response.
“The start of our Food and Drug Administration (FDA) investigational new drug (IND) approved clinical trial formally in the U.S., the largest pharmaceutical market globally, is a significant milestone for Imugene,” said Imugene Managing Director and CEO Leslie Chong.
The first patient in the mid-dose cohort was dosed with the immunotherapy candidate at the Hackensack University Medical Center in New Jersey.
Progression to the mid-dose cohort follows approval from the Dosing Review Committee which determined PD1-Vaxx was safe with no dose-limiting adverse reactions.
PD1-Vaxx is a B-cell cancer immunotherapy and was designed to treat tumors by interfering with PD-1/PD-L1 binding and interaction and producing an anti-cancer effect.
Shares have been trading 5 per cent higher at 10.5 cents at 10:14 am AEDT.
